RUNX1 and acute myeloid leukemia: To further validate these findings, flow cytometry analyses were conducted on a cohort of 76 randomly selected primary human AML specimens which included 19 NKt-AML, 16 NK, 12 intermediate abnormal karyotype, 19 complex karyotype and 10 RUNX1-mutated AML specimens.